TY - JOUR AU - Bray, F. AU - Ferlay, J. AU - Soerjomataram, I. AU - Siegel, R. L. AU - Torre, L. A. AU - Jemal, A. PY - 2018 DA - 2018// TI - Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries JO - CA Cancer J Clin VL - 68 UR - https://doi.org/10.3322/caac.21492 DO - 10.3322/caac.21492 ID - Bray2018 ER - TY - JOUR AU - Schreuders, E. H. AU - Ruco, A. AU - Rabeneck, L. AU - Schoen, R. E. AU - Sung, J. J. AU - Young, G. P. PY - 2015 DA - 2015// TI - Colorectal cancer screening: a global overview of existing programmes JO - Gut. VL - 64 UR - https://doi.org/10.1136/gutjnl-2014-309086 DO - 10.1136/gutjnl-2014-309086 ID - Schreuders2015 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Fedewa, S. A. AU - Ahnen, D. J. AU - Meester, R. G. S. AU - Barzi, A. PY - 2017 DA - 2017// TI - Colorectal cancer statistics, 2017 JO - CA Cancer J Clin VL - 67 UR - https://doi.org/10.3322/caac.21395 DO - 10.3322/caac.21395 ID - Siegel2017 ER - TY - JOUR AU - Siegel, R. AU - Ma, J. AU - Zou, Z. AU - Jemal, A. PY - 2014 DA - 2014// TI - Cancer statistics, 2014 JO - CA Cancer J Clin VL - 64 UR - https://doi.org/10.3322/caac.21208 DO - 10.3322/caac.21208 ID - Siegel2014 ER - TY - JOUR AU - Heinemann, V. AU - Weikersthal, L. F. AU - Decker, T. AU - Kiani, A. AU - Vehling-Kaiser, U. AU - Al-Batran, S. E. PY - 2014 DA - 2014// TI - FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70330-4 DO - 10.1016/S1470-2045(14)70330-4 ID - Heinemann2014 ER - TY - JOUR AU - Goldberg, R. M. AU - Sargent, D. J. AU - Morton, R. F. AU - Fuchs, C. S. AU - Ramanathan, R. K. AU - Williamson, S. K. PY - 2004 DA - 2004// TI - A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.09.046 DO - 10.1200/JCO.2004.09.046 ID - Goldberg2004 ER - TY - JOUR AU - Gramont, A. AU - Figer, A. AU - Seymour, M. AU - Homerin, M. AU - Hmissi, A. AU - Cassidy, J. PY - 2000 DA - 2000// TI - Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer JO - J Clin Oncol VL - 18 UR - https://doi.org/10.1200/JCO.2000.18.16.2938 DO - 10.1200/JCO.2000.18.16.2938 ID - Gramont2000 ER - TY - JOUR AU - Hoff, P. M. AU - Ansari, R. AU - Batist, G. AU - Cox, J. AU - Kocha, W. AU - Kuperminc, M. PY - 2001 DA - 2001// TI - Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study JO - J Clin Oncol VL - 19 UR - https://doi.org/10.1200/JCO.2001.19.8.2282 DO - 10.1200/JCO.2001.19.8.2282 ID - Hoff2001 ER - TY - JOUR AU - Cutsem, E. AU - Kohne, C. H. AU - Hitre, E. AU - Zaluski, J. AU - Chang Chien, C. R. AU - Makhson, A. PY - 2009 DA - 2009// TI - Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer JO - N Engl J Med VL - 360 UR - https://doi.org/10.1056/NEJMoa0805019 DO - 10.1056/NEJMoa0805019 ID - Cutsem2009 ER - TY - JOUR AU - Hurwitz, H. AU - Fehrenbacher, L. AU - Novotny, W. AU - Cartwright, T. AU - Hainsworth, J. AU - Heim, W. PY - 2004 DA - 2004// TI - Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa032691 DO - 10.1056/NEJMoa032691 ID - Hurwitz2004 ER - TY - JOUR AU - Douillard, J. Y. AU - Siena, S. AU - Cassidy, J. AU - Tabernero, J. AU - Burkes, R. AU - Barugel, M. PY - 2014 DA - 2014// TI - Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu141 DO - 10.1093/annonc/mdu141 ID - Douillard2014 ER - TY - JOUR AU - Douillard, J. Y. AU - Cunningham, D. AU - Roth, A. D. AU - Navarro, M. AU - James, R. D. AU - Karasek, P. PY - 2000 DA - 2000// TI - Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial JO - Lancet. VL - 355 UR - https://doi.org/10.1016/S0140-6736(00)02034-1 DO - 10.1016/S0140-6736(00)02034-1 ID - Douillard2000 ER - TY - JOUR AU - Bokemeyer, C. AU - Bondarenko, I. AU - Hartmann, J. T. AU - Braud, F. AU - Schuch, G. AU - Zubel, A. PY - 2011 DA - 2011// TI - Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study JO - Ann Oncol VL - 22 UR - https://doi.org/10.1093/annonc/mdq632 DO - 10.1093/annonc/mdq632 ID - Bokemeyer2011 ER - TY - JOUR AU - Cutsem, E. AU - Kohne, C. H. AU - Lang, I. AU - Folprecht, G. AU - Nowacki, M. P. AU - Cascinu, S. PY - 2011 DA - 2011// TI - Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.33.5091 DO - 10.1200/JCO.2010.33.5091 ID - Cutsem2011 ER - TY - JOUR AU - Weitman, S. D. AU - Glatstein, E. AU - Kamen, B. A. PY - 1993 DA - 1993// TI - Back to the basics: the importance of concentration x time in oncology JO - J Clin Oncol VL - 11 UR - https://doi.org/10.1200/JCO.1993.11.5.820 DO - 10.1200/JCO.1993.11.5.820 ID - Weitman1993 ER - TY - JOUR AU - Kareva, I. AU - Waxman, D. J. AU - Lakka Klement, G. PY - 2015 DA - 2015// TI - Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance JO - Cancer Lett VL - 358 UR - https://doi.org/10.1016/j.canlet.2014.12.039 DO - 10.1016/j.canlet.2014.12.039 ID - Kareva2015 ER - TY - JOUR AU - Therasse, P. AU - Arbuck, S. G. AU - Eisenhauer, E. A. AU - Wanders, J. AU - Kaplan, R. S. AU - Rubinstein, L. PY - 2000 DA - 2000// TI - New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada JO - J Natl Cancer Inst VL - 92 UR - https://doi.org/10.1093/jnci/92.3.205 DO - 10.1093/jnci/92.3.205 ID - Therasse2000 ER - TY - JOUR AU - Trotti, A. AU - Colevas, A. D. AU - Setser, A. AU - Rusch, V. AU - Jaques, D. AU - Budach, V. PY - 2003 DA - 2003// TI - CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment JO - Semin Radiat Oncol VL - 13 UR - https://doi.org/10.1016/S1053-4296(03)00031-6 DO - 10.1016/S1053-4296(03)00031-6 ID - Trotti2003 ER - TY - JOUR AU - Luo, H. Y. AU - Li, Y. H. AU - Wang, W. AU - Wang, Z. Q. AU - Yuan, X. AU - Ma, D. PY - 2016 DA - 2016// TI - Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw101 DO - 10.1093/annonc/mdw101 ID - Luo2016 ER - TY - JOUR AU - Berry, S. R. AU - Cosby, R. AU - Asmis, T. AU - Chan, K. AU - Hammad, N. AU - Krzyzanowska, M. K. PY - 2015 DA - 2015// TI - Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdu272 DO - 10.1093/annonc/mdu272 ID - Berry2015 ER - TY - JOUR AU - Cremolini, C. AU - Marmorino, F. AU - Bergamo, F. AU - Aprile, G. AU - Salvatore, L. AU - Masi, G. PY - 2019 DA - 2019// TI - Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial JO - Eur J Cancer VL - 109 UR - https://doi.org/10.1016/j.ejca.2018.12.028 DO - 10.1016/j.ejca.2018.12.028 ID - Cremolini2019 ER - TY - JOUR AU - Tournigand, C. AU - Cervantes, A. AU - Figer, A. AU - Lledo, G. AU - Flesch, M. AU - Buyse, M. PY - 2006 DA - 2006// TI - OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer–a GERCOR study JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.03.0106 DO - 10.1200/JCO.2005.03.0106 ID - Tournigand2006 ER - TY - JOUR AU - Diaz-Rubio, E. AU - Gomez-Espana, A. AU - Massuti, B. AU - Sastre, J. AU - Abad, A. AU - Valladares, M. PY - 2012 DA - 2012// TI - First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study JO - Oncologist. VL - 17 UR - https://doi.org/10.1634/theoncologist.2011-0249 DO - 10.1634/theoncologist.2011-0249 ID - Diaz-Rubio2012 ER - TY - JOUR AU - Aranda, E. AU - Garcia-Alfonso, P. AU - Benavides, M. AU - Sanchez Ruiz, A. AU - Guillen-Ponce, C. AU - Safont, M. J. PY - 2018 DA - 2018// TI - First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: phase II randomised MACRO2 TTD study JO - Eur J Cancer VL - 101 UR - https://doi.org/10.1016/j.ejca.2018.06.024 DO - 10.1016/j.ejca.2018.06.024 ID - Aranda2018 ER - TY - JOUR AU - Simkens, L. H. AU - Tinteren, H. AU - May, A. AU - Tije, A. J. AU - Creemers, G. J. AU - Loosveld, O. J. PY - 2015 DA - 2015// TI - Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group JO - Lancet. VL - 385 UR - https://doi.org/10.1016/S0140-6736(14)62004-3 DO - 10.1016/S0140-6736(14)62004-3 ID - Simkens2015 ER - TY - JOUR AU - Klement, G. AU - Baruchel, S. AU - Rak, J. AU - Man, S. AU - Clark, K. AU - Hicklin, D. J. PY - 2000 DA - 2000// TI - Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity JO - J Clin Invest VL - 105 UR - https://doi.org/10.1172/JCI8829 DO - 10.1172/JCI8829 ID - Klement2000 ER - TY - JOUR AU - Shi, H. AU - Jiang, J. AU - Ji, J. AU - Shi, M. AU - Cai, Q. AU - Chen, X. PY - 2014 DA - 2014// TI - Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer JO - Cancer Lett VL - 349 UR - https://doi.org/10.1016/j.canlet.2014.04.002 DO - 10.1016/j.canlet.2014.04.002 ID - Shi2014 ER - TY - JOUR AU - Kaneno, R. AU - Shurin, G. V. AU - Kaneno, F. M. AU - Naiditch, H. AU - Luo, J. AU - Shurin, M. R. PY - 2011 DA - 2011// TI - Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells JO - Cell Oncol (Dordr) VL - 34 UR - https://doi.org/10.1007/s13402-010-0005-5 DO - 10.1007/s13402-010-0005-5 ID - Kaneno2011 ER - TY - JOUR AU - Kaneno, R. AU - Shurin, G. V. AU - Tourkova, I. L. AU - Shurin, M. R. PY - 2009 DA - 2009// TI - Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations JO - J Transl Med VL - 7 UR - https://doi.org/10.1186/1479-5876-7-58 DO - 10.1186/1479-5876-7-58 ID - Kaneno2009 ER -